LifeTech Scientific (SEHK:1302) - Share price, News & Analysis

1302 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

1302 Stock Overview

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.

Rewards

Earnings have grown 14.5% per year over the past 5 years

Risk Analysis

No risks detected for 1302 from our risk checks.

LifeTech Scientific Competitors

Price History & Performance

Summary of all time highs, changes and price drops for LifeTech Scientific
Historical stock prices
Current Share Price	HK$2.89
52 Week High	HK$5.86
52 Week Low	HK$2.01
Beta	1.13
1 Month Change	31.96%
3 Month Change	6.64%
1 Year Change	-41.50%
3 Year Change	103.52%
5 Year Change	56.22%
Change since IPO	1,056.00%

Recent News & Updates

Jun 15

A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)

In this article we are going to estimate the intrinsic value of LifeTech Scientific Corporation ( HKG:1302 ) by...

Apr 03

Returns At LifeTech Scientific (HKG:1302) Are On The Way Up

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Shareholder Returns

	1302	HK Medical Equipment	HK Market
7D	7.4%	15.2%	2.1%
1Y	-41.5%	-60.3%	-23.3%

Return vs Industry: 1302 exceeded the Hong Kong Medical Equipment industry which returned -60.3% over the past year.

Return vs Market: 1302 underperformed the Hong Kong Market which returned -23.3% over the past year.

Price Volatility

Is 1302's price volatile compared to industry and market?
1302 volatility
1302 Average Weekly Movement	7.6%
Medical Equipment Industry Average Movement	8.4%
Market Average Movement	7.0%
10% most volatile stocks in HK Market	13.8%
10% least volatile stocks in HK Market	3.3%

Stable Share Price: 1302 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 1302's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	945	Yuehui Xie	https://www.lifetechmed.com

LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers.

LifeTech Scientific Fundamentals Summary

How do LifeTech Scientific's earnings and revenue compare to its market cap?
1302 fundamental statistics
Market Cap	CN¥11.40b
Earnings (TTM)	CN¥292.47m
Revenue (TTM)	CN¥925.33m

39.0x

P/E Ratio

12.3x

P/S Ratio

Is 1302 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
1302 income statement (TTM)
Revenue	CN¥925.33m
Cost of Revenue	CN¥177.80m
Gross Profit	CN¥747.53m
Other Expenses	CN¥455.06m
Earnings	CN¥292.47m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	0.063
Gross Margin	80.79%
Net Profit Margin	31.61%
Debt/Equity Ratio	0%

How did 1302 perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is 1302 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1302?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 1302. This is calculated by dividing 1302's market cap by their current preferred multiple.
What is 1302's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	CN¥11.40b

1302 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	10.7x
Enterprise Value/EBITDA	23.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 1302's PE Ratio compare to its peers?

1302 PE Ratio vs Peers

The above table shows the PE ratio for 1302 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PE	Estimated Growth	Market Cap
Peer Average	46.3x

Forward PE

Price-To-Earnings vs Peers: 1302 is good value based on its Price-To-Earnings Ratio (39x) compared to the peer average (46.3x).

Price to Earnings Ratio vs Industry

How does 1302's PE Ratio compare vs other companies in the Medical Equipment Industry?

Price-To-Earnings vs Industry: 1302 is expensive based on its Price-To-Earnings Ratio (39x) compared to the Hong Kong Medical Equipment industry average (17.2x)

Price to Earnings Ratio vs Fair Ratio

What is 1302's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1302 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	39x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1302's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 1302 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1302 (HK$2.89) is trading above our estimate of fair value (HK$2.55)

Significantly Below Fair Value: 1302 is trading above our estimate of fair value.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1302's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is LifeTech Scientific forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

18.2%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as LifeTech Scientific has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Examine LifeTech Scientific's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
LifeTech Scientific competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has LifeTech Scientific performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

14.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 1302 has high quality earnings.

Growing Profit Margin: 1302's current net profit margins (31.6%) are lower than last year (33.6%).

Past Earnings Growth Analysis

Earnings Trend: 1302's earnings have grown by 14.5% per year over the past 5 years.

Accelerating Growth: 1302's earnings growth over the past year (35.4%) exceeds its 5-year average (14.5% per year).

Earnings vs Industry: 1302 earnings growth over the past year (35.4%) underperformed the Medical Equipment industry 35.4%.

Return on Equity

High ROE: 1302's Return on Equity (11.2%) is considered low.

Discover strong past performing companies

Financial Health

How is LifeTech Scientific's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: 1302's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥481.9M).

Long Term Liabilities: 1302's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥171.7M).

Debt to Equity History and Analysis

Debt Level: 1302 is debt free.

Reducing Debt: 1302 has no debt compared to 5 years ago when its debt to equity ratio was 22.9%.

Debt Coverage: 1302 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 1302 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Dividend

What is LifeTech Scientific current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1302's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1302's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1302's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1302's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: 1302 is not paying a notable dividend for the Hong Kong market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 1302 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

8.2yrs

Average board tenure

CEO

Yuehui Xie (52 yo)

7.25yrs

Tenure

CN¥14,073,000

Compensation

Mr. Yuehui Xie has been the Chief Executive Officer at LifeTech Scientific Corporation since March 2, 2015. Mr. Xie is responsible for overall strategic planning and management of LifeTech Scientific Corpo...

CEO Compensation Analysis

Compensation vs Market: Yuehui's total compensation ($USD2.10M) is above average for companies of similar size in the Hong Kong market ($USD590.64K).

Compensation vs Earnings: Yuehui's compensation has increased by more than 20% in the past year.

Board Members

Experienced Board: 1302's board of directors are considered experienced (8.2 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/25 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31